Stable Tripeptide Compounds for Anti-Inflammatory Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory treatments are inadequate due to low efficacy, delayed response, temporary effects, undesirable side effects, and lack of selectivity, and existing tripeptide compounds like H-Lys-Pro-Val are unstable and have poor bioavailability.
Innovation Solution
Development of novel tripeptide compounds with specific amino acid combinations, such as H-(L)-Lys-(D)-Pro-Aib-OH and H-(L)-Lys-(L)-Pro-Nα-methyl-(L)-Thr-OH, which are more stable, have improved bioavailability, and are free from toxic side effects, used as pharmaceutical active compounds for treating inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing tripeptide compounds like H-Lys-Pro-Val are used for anti-inflammatory treatment, then some anti-inflammatory effect is achieved, but the compounds are unstable and have poor bioavailability
Solution Approach 1:
The patent modifies the chemical structure of tripeptide compounds by changing parameters such as introducing Nα-methyl or Nα,Nα-dimethyl amino acid residues at specific positions (AA1 or AA2) in the tripeptide sequence. These structural parameter changes enhance the metabolic stability and bioavailability of the compounds while maintaining their anti-inflammatory activity, directly resolving the contradiction between stability and bioavailability.
Solution Approach 2:
The patent creates composite peptide structures by combining different amino acid residues (e.g., combining Nα-methyl amino acids with standard amino acids like Proline and Aib) to form novel tripeptide compounds. This composite approach allows the integration of stability-enhancing residues with biologically active sequences, simultaneously improving both stability and bioavailability properties.
2Reliability
If existing anti-inflammatory treatments are used, then inflammation is treated, but the treatments exhibit low, delayed or only temporary efficacy
Solution Approach 1:
The patent optimizes the pharmacokinetic parameters of tripeptide compounds through structural modifications, particularly introducing Nα-methyl or Nα,Nα-dimethyl amino acid residues that enhance cellular uptake and reduce metabolic degradation. These parameter changes result in faster onset of action and sustained anti-inflammatory efficacy, eliminating the delays and temporary effects associated with conventional treatments.
3Reliability
If existing anti-inflammatory treatments are used, then inflammation is treated, but undesirable side effects and lack of selectivity occur
Solution Approach 1:
The patent enhances the selectivity of tripeptide compounds by introducing specific amino acid residues at defined positions in the sequence. The Nα-methyl or Nα,Nα-dimethyl amino acid residues at AA1 or AA2 positions create local structural features that improve binding specificity to target inflammatory pathways while sparing other physiological processes, thereby reducing off-target side effects.
Data Source
AI summary
The present invention relates to tripeptide compounds according to the general formula (1) and their use as a medicament, in particular as anti-inflammatory agents.